{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:46Z","timestamp":1790199586810,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00277-021-04685-8","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T06:35:10Z","timestamp":1634106910000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era"],"prefix":"10.1007","volume":"101","author":[{"given":"Julio","family":"del R\u00edo-Garma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Bobillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faustino","family":"Garc\u00eda-Candel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Garc\u00eda-Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Abril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Vidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jes\u00fas","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Arbona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Mart\u00edn-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Rom\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Viejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Garcia-Erce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the \u201cRegistro Espa\u00f1ol de la P\u00farpura Trombocitop\u00e9nica Tromb\u00f3tica (REPTT)\u201d, and\u00a0the \u201cGrupo Espa\u00f1ol de Af\u00e9resis (GEA)\u201d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"issue":"21","key":"4685_CR1","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129(21):2836\u20132846","journal-title":"Blood"},{"issue":"1","key":"4685_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2141.2008.07292.x","volume":"143","author":"J del R\u00edo-Garma","year":"2008","unstructured":"del R\u00edo-Garma J, Alvarez-Larr\u00e1n A, Mart\u00ednez C et al (2008) Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 143(1):39\u201345","journal-title":"Br J Haematol"},{"issue":"7","key":"4685_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ajh.23455","volume":"88","author":"S Chaturvedi","year":"2013","unstructured":"Chaturvedi S, Carcioppolo D, Zhang L, McCrae KR (2013) Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. Am J Hematol 88(7):560\u2013565","journal-title":"Am J Hematol"},{"issue":"5","key":"4685_CR4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/bjh.13658","volume":"171","author":"PK Bendapudi","year":"2015","unstructured":"Bendapudi PK, Li A, Hamdan A et al (2015) Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol 171(5):836\u2013844","journal-title":"Br J Haematol"},{"issue":"8","key":"4685_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","volume":"97","author":"Y Benhamou","year":"2012","unstructured":"Benhamou Y, Assi\u00e9 C, Boelle PY et al (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 97(8):1181\u20131186","journal-title":"Haematologica"},{"issue":"2","key":"4685_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jth.12790","volume":"13","author":"Y Benhamou","year":"2015","unstructured":"Benhamou Y, Boelle PY, Baudin B et al (2015) Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 13(2):293\u2013302","journal-title":"J Thromb Haemost"},{"issue":"10","key":"4685_CR7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","volume":"1","author":"EE Page","year":"2017","unstructured":"Page EE, Kremer Hovinga JA, Terrell D-R, Vesely SK, George JN (2017) Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 1(10):590\u2013600","journal-title":"Blood Adv"},{"issue":"4","key":"4685_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","volume":"130","author":"F Alwan","year":"2017","unstructured":"Alwan F, Vendramin C, Vanhoorelbeke K et al (2017) Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood 130(4):466\u2013471","journal-title":"Blood"},{"issue":"1","key":"4685_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3324\/haematol.2018.198275","volume":"104","author":"EM Staley","year":"2019","unstructured":"Staley EM, Cao W, Pham HP et al (2019) Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. Haematologica 104(1):166\u2013175","journal-title":"Haematologica"},{"key":"4685_CR10","doi-asserted-by":"crossref","unstructured":"Colling M, Sun L, Upadhyay V et al (2020) Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. Transfusion 60(4):841\u2013846","DOI":"10.1111\/trf.15721"},{"issue":"5","key":"4685_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1055\/s-0039-1679907","volume":"119","author":"I Mancini","year":"2019","unstructured":"Mancini I, Pontiggia S, Palla R et al (2019) Clinical and laboratory features of patients with acquired thrombotic thrombocytopenic purpura: fourteen years of the Milan TTP Registry. Thromb Haemost 119(5):695\u2013704","journal-title":"Thromb Haemost"},{"issue":"6","key":"4685_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374(6):511\u2013522","journal-title":"N Engl J Med"},{"issue":"4","key":"4685_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland S-R, Peyvandi F et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380(4):335\u2013346","journal-title":"N Engl J Med"},{"issue":"6","key":"4685_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF01696619","volume":"70","author":"A Pereira","year":"1995","unstructured":"Pereira A, Mazzara R, Monteagudo J et al (1995) Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 70(6):319\u2013323","journal-title":"Ann Hematol"},{"issue":"4","key":"4685_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1538-7836.2009.03285.x","volume":"7","author":"C Hughes","year":"2009","unstructured":"Hughes C, McEwan J-R, Longair I et al (2009) Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost 7(4):529\u2013536","journal-title":"J Thromb Haemost"},{"issue":"8","key":"4685_CR16","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","volume":"115","author":"JA Kremer Hovinga","year":"2010","unstructured":"Kremer Hovinga JA, Vesely SK, Terrell DR, L\u00e4mmle B, George JN (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115(8):1500\u20131511","journal-title":"Blood"},{"issue":"2","key":"4685_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardisation of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15(2):312\u2013322","journal-title":"J Thromb Haemost"},{"key":"4685_CR18","doi-asserted-by":"crossref","unstructured":"Posner JB, Saper CB, Schiff N, Plum F (2007) Pathophysiology of signs and symptoms of coma. In: Gilman S (ed) Plum and Posner\u2019s diagnosis of stupor and coma, 4th edn. Oxford University Press, New York, pp 3\u201337","DOI":"10.1093\/med\/9780195321319.003.0010"},{"issue":"5","key":"4685_CR19","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1055\/s-0037-1614780","volume":"82","author":"HE Gerritsen","year":"1999","unstructured":"Gerritsen HE, Turecek PL, Schwarz HP, L\u00e4mmle B, Furlan M (1999) Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 82(5):1386\u20131389","journal-title":"Thromb Haemost"},{"issue":"1","key":"4685_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","volume":"129","author":"K Kokame","year":"2005","unstructured":"Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129(1):93\u2013100","journal-title":"Br J Haematol"},{"issue":"9","key":"4685_CR21","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/j.1538-7836.2008.03099.x","volume":"6","author":"A Tripodi","year":"2008","unstructured":"Tripodi A, Peyvandi F, Chantarangkul V et al (2008) Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 6(9):1534\u20131541","journal-title":"J Thromb Haemost"},{"issue":"25","key":"4685_CR22","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","volume":"125","author":"FA Sayani","year":"2015","unstructured":"Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125(25):3860\u20133867","journal-title":"Blood"},{"issue":"12","key":"4685_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4330\/wjc.v10.i12.254","volume":"10","author":"SL Wiernek","year":"2018","unstructured":"Wiernek SL, Jiang B, Gustafson GM, Dai X (2018) Cardiac implications of thrombotic thrombocytopenic purpura. World J Cardiol 10(12):254\u2013266","journal-title":"World J Cardiol"},{"issue":"2","key":"4685_CR24","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.amjmed.2020.06.020","volume":"134","author":"N Balasubramaniyam","year":"2021","unstructured":"Balasubramaniyam N, Yandrapalli S, Kolte D et al (2021) Cardiovascular complications and their association with mortality in patients with thrombotic thrombocytopenic purpura. Am J Med 134(2):e89\u2013e97","journal-title":"Am J Med"},{"issue":"6","key":"4685_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","volume":"137","author":"P Coppo","year":"2021","unstructured":"Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Big\u00e9 N et al (2021) A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 137(6):733\u2013742","journal-title":"Blood"},{"issue":"13","key":"4685_CR26","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1182\/blood.2020007599","volume":"137","author":"T Dutt","year":"2021","unstructured":"Dutt T, Shaw RJ, Stubbs MJ et al (2021) Real-world evidence of caplacizumab use in the management of acute TTP. Blood 137(13):1731\u20131740","journal-title":"Blood"},{"key":"4685_CR27","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","volume":"4(13)","author":"LA Volker","year":"2020","unstructured":"Volker LA, Kaufeld J, Miesbach W, Br\u00e4hler S, Reinhardt M, K\u00fchne L et al (2020) Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv 4(13):3085\u20133092","journal-title":"Blood Adv"},{"issue":"11","key":"4685_CR28","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1111\/jth.15045","volume":"18","author":"LA V\u00f6lker","year":"2020","unstructured":"V\u00f6lker LA, Brinkkoetter PT, Kn\u00f6bl PN, Krstic M, Kaufeld J, Menne J, Buxhofer-Ausch V, Miesbach W (2020) Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab. J Thromb Haemost 18(11):3061\u20133066","journal-title":"J Thromb Haemost"},{"issue":"14","key":"4685_CR29","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","volume":"137","author":"A Cuker","year":"2021","unstructured":"Cuker A, Cataland SR, Coppo P et al (2021) Redefining outcomes in immune TTP: an international working group consensus report. Blood 137(14):1855\u20131861","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04685-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04685-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04685-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T15:09:57Z","timestamp":1641222597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04685-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4685"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04685-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"5 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.D.R.G. has received speaker fee from Takeda and consultancy for Sanofi. J.D.L.R: Consultancy for Ablynx\/Sanofi, AMGEN, Celgene, Janssen, Takeda. C.P: Consultancy for Ablynx\/Sanofi, Novartis. I.R: Ownership interest in Grifols. AP: consultancy fees from Ablynx\/Sanofi. All other authors declare that they have no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}